In many cases, patient susceptibility to BC is thought to have a genetic component, with heterozygous high-penetrance variants in the BRCA1 and BRCA2 genes accounting for 50-80% of such variation and BRCA1/2 gene sequences accounting for approximately 20% of cases of familial BC (9). The gene discussed is BRCA2; the disease is breast cancer.